OTLK — Outlook Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $141.93m
- $142.34m
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 8.02 | 12.5 | 14.5 | 17.4 | 23.4 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 13.5 | 17.9 | 21.5 | 27.5 | 31 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.18 | 0.494 | 0.275 | 0.07 | 0.026 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 17.1 | 19.7 | 22.8 | 28.5 | 32.3 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 20.3 | 15.9 | 6.75 | 19.7 | 46.7 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 27.9 | 16.9 | 18.2 | 19.8 | 46.7 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | -10.8 | 2.83 | 4.61 | 8.74 | -14.4 |
Total Liabilities & Shareholders' Equity | 17.1 | 19.7 | 22.8 | 28.5 | 32.3 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |